Nanovibronix Stock Today
| NAOV Stock | USD 0.73 0.02 2.82% |
Performance7 of 100
| Odds Of DistressLess than 38
|
NanoVibronix is selling for under 0.73 as of the 28th of November 2024; that is 2.82 percent increase since the beginning of the trading day. The stock's lowest day price was 0.71. NanoVibronix has about a 38 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for NanoVibronix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 27th of June 2017 | Category Healthcare | Classification Health Care |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York. The company has 3.75 M outstanding shares of which 86.16 K shares are now shorted by private and institutional investors with about 0.47 trading days to cover. More on NanoVibronix
Moving against NanoVibronix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NanoVibronix Stock Highlights
| CEO, Director | Brian Murphy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNanoVibronix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NanoVibronix's financial leverage. It provides some insight into what part of NanoVibronix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NanoVibronix (NAOV) is traded on NASDAQ Exchange in USA. It is located in 969 Pruitt Avenue, Tyler, TX, United States, 77569 and employs 10 people. NanoVibronix is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.74 M. NanoVibronix conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 3.75 M outstanding shares of which 86.16 K shares are now shorted by private and institutional investors with about 0.47 trading days to cover.
NanoVibronix currently holds about 3.94 M in cash with (3.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14.
Check NanoVibronix Probability Of Bankruptcy
Ownership AllocationRoughly 85.82 % of NanoVibronix outstanding shares are held by general public with 0.69 pct. owned by insiders and only 13.49 % by institutional investors.
Check NanoVibronix Ownership Details
NanoVibronix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-09-30 | 278.7 K | |
| Vanguard Group Inc | 2024-09-30 | 30.2 K | |
| Renaissance Technologies Corp | 2024-09-30 | 26.6 K | |
| Citadel Advisors Llc | 2024-09-30 | 23.8 K | |
| Geode Capital Management, Llc | 2024-09-30 | 22.8 K | |
| Tower Research Capital Llc | 2024-06-30 | 6.1 K | |
| Ubs Group Ag | 2024-06-30 | 46.0 | |
| Bank Of America Corp | 2024-06-30 | 17.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Amtrust Financial Services Inc | 2024-06-30 | 0.0 |
NanoVibronix Historical Income Statement
NanoVibronix Stock Against Markets
NanoVibronix Corporate Management
| CPA CPA | CFO Officer | Profile | |
| M Harrison | VP Sales | Profile | |
| Amir Rippel | Vice Marketing | Profile | |
| Stephen CPA | Chief Officer | Profile | |
| Harold MD | Chief Director | Profile | |
| Lindsey Harrison | Vice Sales | Profile |
Additional Tools for NanoVibronix Stock Analysis
When running NanoVibronix's price analysis, check to measure NanoVibronix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoVibronix is operating at the current time. Most of NanoVibronix's value examination focuses on studying past and present price action to predict the probability of NanoVibronix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoVibronix's price. Additionally, you may evaluate how the addition of NanoVibronix to your portfolios can decrease your overall portfolio volatility.